The Pharmaceutical Industry in Figures

EFPIA's annual report on the pharmaceutical industry in figures is now available, a 40-page, chart-filled conglomeration of data on the industry within the EU and how it compares to the global drug industry. After a thorough scan, here are some of the more interesting tidbits:
  • Pharma and biotech represent 17% of total EU business R&D investment, yet just 3.5% of total EU manufacturing value-added (p. 1).
  • Total pharma R&D expenditures in the EU and U.S. dipped in 2009, a result of the global economic slump. The U.S. remains ahead of the EU in terms of such expenditures (p. 2).
  • Drug industry growth in emerging markets (including Asia, Africa, and Latin America) is roughly twice what it is in the EU and U.S. (p. 3).
  • The U.S. continues to be the "leading discoverer of new molecules" in the world, though as the report points out the number of NME's approved compared to those in development continues to be miniscule regardless of geography (p. 10).
  • The U.S. biotech industry represents approximately 75% of the entire global biotech industry, with the EU at less than 20% (p. 12)
  • The EU remains the vaccine hub, with approximately 90% of all global vaccine production originating from European manufacturers. Approximately half of all vaccine sales are in North America (p. 13).
  • Patients in the EU pay roughly 18% of the tab for drug costs; in the Netherlands, however, patients pay only 0.7% of their medicine costs (p. 25).

--Paul Thomas

 

 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

  • <p>Hello,I love reading through your blog, I wanted to leave a little comment to support you and wish you a good continuation. Wishing you the best of luck for all your blogging efforts.<a href="http://www.actualtest.ws/actualtests-650-251.html">650-251 papers</a>// <a href="http://www.actualtest.ws/actualtests-650-296.html">650-296 exam questions</a>// <a href="http://www.actualtest.ws/actualtests-650-297.html">650-297 questions</a>// <a href="http://www.actualtest.ws/actualtests-650-367.html">650-367 exam questions</a>// <a href="http://www.actualtest.ws/actualtests-650-368.html">650-368 exam questions</a>// <a href="http://www.actualtest.ws/actualtests-650-369.html">650-369 exam questions</a>// <a href="http://www.actualtest.ws/actualtests-650-377.html">650-377 pdf</a>// <a href="http://www.actualtest.ws/actualtests-650-378.html">650-378 exam questions</a>// </p>

    Reply

  • <p>Foreclosures are setting new records again, this time not in their overall numbers, but in the time it <a href="http://www.luxury-vibrators.com/G-Spot-Vibrators-c2.html">g-spot vibrators</a> is taking for all of these properties to be processed through the legal system. </p>

    Reply

  • <p>The U.S. continues to be the "leading discoverer <a href="http://www.sure-braindumps.com/JN0-343.htm">JN0-343</a> of new molecules" in the world, though as the report points out the number of NME's approved compared to those in development continues to be miniscule regardless of geography (p. 10). The U.S. biotech industr <a href="http://www.sure-braindumps.com/JN0-360.htm">JN0-360</a> represents approximately 75% of the entire global biotech industry, with the EU at less than 20% (p. 12) The EU remains the vaccine hub, with approximately 90% of all global vaccine production originating from European manufacturers. Approximately half of all vaccine sales are in <a href="http://www.sure-braindumps.com/JN0-632.htm">JN0-632</a> North America (p. 13). Patients in the EU pay roughly 18% of the tab for drug costs; in the Netherlands, however, patients <a href="http://www.sure-braindumps.com/JN0-643.htm">JN0-643</a> pay only 0.7% of their medicine costs (p. 25).</p>

    Reply

RSS feed for comments on this page | RSS feed for all comments